title: Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
authors.affiliation: Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. fmarsha@emory.edu
authors.forename: Fray F
authors.initials: FF
authors.lastname: Marshall